Researchers investigated the potential association between plasma apolipoprotein M (APOM) levels and the risk of adverse ...

点击蓝字关注我们【导读】脑转移是表皮生长因子受体（epidermal growth factor receptor， ...

肺癌脑转移是肺癌患者治疗失败和死亡的重要原因，对于携带表皮生长因子受体（EGFR）突变的肺腺癌（LUAD）患者而言，脑转移更是导致靶向治疗失效的关键因素。在亚洲非吸烟的 LUAD 患者中，EGFR 突变比例高达 66.3%，且近 29% 的患者在初诊时就已发现脑转移。经过 3 年酪氨酸激酶抑制剂（TKI）治疗，脑转移的患病率从初诊时的 25% 飙升至 45% 。尽管脑转移危害巨大，但目前对于 ...

StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a research note published on Tuesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

脑转移现象在肺腺癌患者中并不罕见，尤其是在66.3%带有表皮生长因子受体（EGFR）突变的非吸烟患者中更是高达29%在初诊时已被检测到脑转移。这一数据让人不禁担忧，越来越多的患者在接受靶向治疗后，脑转移的发生率从初诊时的25%上升至45%。如何应对这一挑战，成为了医学界亟待研究的问题。

Also emerging are oral therapies including Bristol-Myers Squibb's S1P therapy Zeposia (ozanimod) – with Arena Pharma's etrasimod following closely after in phase 3 – as well as newer JAK ...

NICE said it was able to carry out a rapid review of the S1P receptor modulator thanks to a recently adopted simpler technology appraisal process that cut around eight weeks off the timeline.

Manipal Institute of Virology (MIV) celebrated its Annual Day and Alumni Meet 2025 at Dr TMA Pai Auditorium, MAHE, Manipal, ...

The risk of disease activity in going to a less effective DMT was higher in younger adults and those having prior ...

eLife is a non-profit organisation inspired by research funders and led by scientists. Our mission is to help scientists accelerate discovery by operating a platform for research communication that ...